drugset / Trial / NCT01569048

Randomized Controlled Trial to Evaluate of Dexmedetomidine for the Effect on Operative Visibility in Patients Undergoing Endoscopic Sinus Surgery

NCT01569048 ↗

Phase 4 Completed 66 enrolled Yonsei University
RandomizedSingle-groupDouble-blindPrevention

Summary

Various maneuvers are commonly used to achieve the ideal operative field necessary for successful endoscopic sinus surgery (ESS). Dexmedetomidine, a potent alpha2 adrenoceptor agonist which dose-dependently reduces arterial blood pressure and heart rate, decreases the hemodynamic and catecholamine response. And dexmedetomidine has an effect of peripheral vasoconstriction thus it is thus theologically appropriate for reducing bleeding during intranasal operation. The aim of this study is to compare the effect of dexmedetomidine, an alpha2-adrenoreceptor agonist, on intraoperative bleeding, propofol requirement and postoperative profiles to remifentanil , an ultrashort-acting opioid.

Timeline

Start
2012-03
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 0.5 ug/kg —
Comparator Remifentanil Small molecule 2 ng/ml —
Comparator Remifentanil Small molecule 4 ng/ml —
Background Propofol Small molecule 2 ug/ml —
Background Propofol Small molecule 4 ug/ml —